The U.S. Food and Drug Administration (FDA) has issued an Abbreviated New Drug Application (ANDA) number ANDA084080 for a promethazine hydrochloride product submitted by TABLICAPS.
The product is an oral tablet containing 12.5 mg of promethazine hydrochloride, classified under the route "ORAL" and dosage form "TABLET". The sponsor indicated that the product is not a reference drug and is listed with a marketing status of "Discontinued".
No reference standard was provided for this submission.
Actualizaciones regulatorias19 sept 2026•1 min de lectura
FDA Issues ANDA084080 for Promethazine Hydrochloride Tablet
FDA assigned ANDA084080 to TABLICAPS for an oral 12.5 mg promethazine hydrochloride tablet, now listed as discontinued.
Recopilado por el equipo de PharmaCountry · Fuente: FDA.gov
Calificaciones
(0)
(0)
(0)
(0)
(0)
Más artículos
Ver todos los artículosInvestigación e Informes
Global Finished Dosage Manufacturing Landscape 2026
5 oct 2026
Actualizaciones regulatoriasKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept 2026
AnálisisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept 2026
Deja tu valoración